A61K 47/68031
The drug being an auristatin
Official title: {the drug being an auristatin}
A61K47/68031 (The drug being an auristatin) appears on 693 US grants and 1,656 published applications in this corpus.
Search patents in A61K- Granted patents
- 693
- Published applications
- 1,656
- Assignees
- 466
- Inventors
- 3,113
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 5 |
| 2006 | 0 | 2 |
| 2007 | 0 | 2 |
| 2008 | 1 | 14 |
| 2009 | 3 | 11 |
| 2010 | 9 | 12 |
| 2011 | 7 | 15 |
| 2012 | 8 | 29 |
| 2013 | 14 | 24 |
| 2014 | 15 | 35 |
| 2015 | 20 | 55 |
| 2016 | 19 | 72 |
| 2017 | 38 | 81 |
| 2018 | 47 | 105 |
| 2019 | 53 | 107 |
| 2020 | 57 | 102 |
| 2021 | 70 | 133 |
| 2022 | 58 | 128 |
| 2023 | 75 | 147 |
| 2024 | 78 | 206 |
| 2025 | 75 | 209 |
| 2026 | 46 | 162 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Anti-Nectin-4 antibody, conjugate including the same, and application thereof6 Oct 2026US 12,753,230 B2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- CD38 antibody drug conjugate15 Sep 2026US 12,734,209 B2Ogory, Inc.
- Compounds capable of binding to proteins and conjugates obtained from these compounds8 Sep 2026US 12,728,170 B2Mc Saf
- Antigen-binding protein constructs and uses thereof1 Sep 2026US 12,721,901 B2Mythic Therapeutics, Inc.
- Antigen binding molecules and methods thereof II1 Sep 2026US 12,723,088 B2Agency for Science, Technology and Research
- Delivery of dual payload of mmaf or mmae and tlr7 agonists8 Oct 2026US 2026/0306648 A1The Research Foundation for The State University of New York
- Methods for treating patients with locally advanced or metastatic urothelial cancer with antibody drug conjugates (adc) that bind 191p4d12 proteins in combination with pembrolizumab8 Oct 2026US 2026/0306649 A1Agensys, Inc.
- Anti-cmet antibody, antibody-drug conjugate, and preparation method therefor and use thereof8 Oct 2026US 2026/0306651 A1MediLink Therapeutics (Suzhou) Co., Ltd.
- Modified antibodies, antibody fragments thereof, and antibody-drug conjugates1 Oct 2026US 2026/0295063 A1Innovent Biologics (Suzhou) Co., Ltd.
- Human cd6 binding molecules24 Sep 2026US 2026/0284212 A1The Cleveland Clinic Foundation
Most cited
By later US patents
- Monomethylvaline compounds capable of conjugation to ligands486US 7,498,298 B2Seattle Genetics, Inc. · 2009
- Cysteine engineered antibodies and conjugates485US 7,521,541 B2Genetech, Inc. · 2009
- Monomethylvaline compounds capable of conjugation to ligands152US 7,745,394 B2Seattle Genetics, Inc. · 2010
- Cysteine engineered antibodies and conjugates149US 7,855,275 B2Genentech, Inc. · 2010
- Monomethylvaline compounds capable of conjugation to ligands148US 7,964,566 B2Seattle Genetics, Inc. · 2011